Teos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.

The 12-year-old company had been collaborating with British pharmaceutical giant GlaxoSmithKline on an immuno-oncology drug ...

Fintel reports that on May 28, 2025, Wedbush downgraded their outlook for iTeos Therapeutics (NasdaqGM:ITOS) from Outperform to Neutral. Analyst Price Forecast Suggests 153.48% Upside As of May 6, ...

iTeos Therapeutics (NASDAQ:ITOS) added ~25% in the premarket on Wednesday after the immuno-oncology drug developer announced plans to wind down operations as an outcome of a strategic review aimed ...

WATERTOWN, Mass. and GOSSELIES, Belgium, May 28, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Investors might want to bet on iTeos Therapeutics, Inc. (ITOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings ...

May 28 (Reuters) - ITeos Therapeutics (ITOS.O), opens new tab plans to wind down its operations and sell its assets, including experimental cancer treatments and an obesity drug, the company said ...

ITeos Therapeutics is throwing in the towel. Two weeks after axing its GSK-partnered TIGIT candidate, the biotech has decided to wind down operations, sell its assets and return as much of its $ ...

When InvestingPro’s Fair Value model identified iTeos Therapeutics (NASDAQ:ITOS) as significantly undervalued on March 31, 2025, the stock was trading at just $5.97. Today, barely three months ...